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1. Translation of OATP1B1 and BCRP Inhibition on the Systemic Exposure of 
Rosuvastatin: Linking Drug Interaction Mechanism to Derived 
Pharmacokinetic Translation of Parameters 
Sweta Patela, Marta Johnsonb, Maciej J. Zamek-Gliszczynskib, Joseph W. Pollib, Xiusheng 
MiaobMechanistic Safety & Disposition, GlaxoSmithKline, King of Prussia, PA 
Transporters play a critical role in the absorption, distribution and elimination of drugs, and they 
determine plasma and tissue concentrations of a broad variety of drugs. Inhibition or induction 
of transporters by co-administered drugs can alter the pharmacokinetics and pharmacodynamics 
of the victim drug. This study investigated the clinically observed drug-drug interactions (DDIs) 
for rosuvastatin attributable to inhibition of intestinal efflux transporter breast cancer resistance 
protein (BCRP) and hepatic uptake transporter organic anion transporting polypeptide 1B1 
(OATP1B1). Our hypothesis is that changes in rosuvastatin pharmacokinetic parameters AUC and 
Cmax are correlated with three mechanisms of transporter inhibition: (1) mainly BCRP, (2) 
mainly OATP1B1, and (3) inhibition of both BCRP and OATP1B1. Rifampicin, cyclosporine, 
asunaprevir, fostamatinib and velpatasvir were selected as representative perpetrator drugs, and 
their IC50 values of BCRP and OATP1B1 were generated using the BCRP vesicular transport assay 
and OATP1B1 (HEK293-MSRII Frozen cells) imaging assay, respectively. Based on data analysis, 
we concluded that (1) BCRP interactions in the gastrointestinal tract can increase the systemic 
exposure of rosuvastatin with no marked difference between the increases in AUC and Cmax (2) 
hepatic OATP1B1 drug interactions usually cause significant increases of rosuvastatin systemic 
exposure with a more marked effect on Cmax relative to AUC (3) Inhibition of both BCRP and 
OATP1B1 usually results in significant exposure increase of rosuvastatin, and there is marked 
difference between AUC and Cmax increases. 
 
2. Enhancing Accumulation and Penetration of Semifluorinated 
Nanoassemblies with iRGD for Targeted Drug Delivery to Solid Tumors 
Montira Tangsangasaksri1, Sandro Mecozzi1,2, 1Pharmaceutical Sciences Division, School of 
Pharmacy, University of Wisconsin-Madison, 2Department of Chemistry, University of 
Wisconsin-Madison 
Limited tumor penetration is one of major hurdles for achieving high therapeutic efficiency in 
nanoscale drug delivery system due to heterogeneity of tumor environments. Most of 
nanoparticles, at the same time, encounter a limited accumulation through the enhanced 
permeability and retention (EPR) effect where they passively extravasate to the tumor site via a 
leaky vasculature, leading to a lower nanoparticle efficiency. iRGD, an internalizing RGD, is a 
cyclic tumor- penetrating peptide that possesses RGD and CendR motifs that are responsible for 
improving tumor accumulation and penetration, respectively. iRGD actively targets tumors by 
binding to cancerous cells overexpressing αv integrins through RGD motif. The exposed CendR 
motif, after proteolytic cleavage, specifically binds to neuropilin-1 receptors initiating transcytosis  
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pathway, thus allowing tumor  penetration. Herein,  we  have  developed    iRGD  functionalized  
tri- perfluoro-tert-butyl  (PFtBTRI)-containing  semifluorinated  triblock  copolymer.  Our 
previous studies have demonstrated that the fluorous segment in the triblock copolymer 
improved the stability of the corresponding self-assembled nanoparticles, resulting in a longer in 
vivo blood circulation time. The iRGD ligand was successfully conjugated to the semifluorinated 
triblock copolymer. Our semifluorinated polymer showed a low critical micelle concentration 
(CMC) of 11.5 µM with an aggregation number of 57 ± 1. The self-assembled micelles prepared 
from iRGD functionalized semifluorinated polymer maintained a small size similar to that of the 
non- functionalized micelles. Our results show a negligible cytotoxicity of the synthesized polymer 
to breast cancer cell line even at a high concentration (1 mM). A high encapsulation efficiency of 
various hydrophobic drugs was achieved. Moreover, the cellular uptake of iRGD conjugated 
micelles was significantly higher compared to non-functionalized micelles. Results on the efficacy 
of this delivery system will be presented. 
 
3. In-vitro pH responsive drug release kinetics of alkali extracted carrageenan 
crosslinked genipin/chitosan matrices 
Kushaal Raja, Roselyn Lataa, David Rohindraa* and Firoz Ghazalib School of Biological and 
Chemical Sciences, Faculty of Science Technology and Environment, University of the South 
Pacific, Suva, Fiji. Douglas Pharmaceutical Fiji Limited, Nadi, Fiji. 
In this study, carrageenan, a sulphated polysaccharide was extracted using KOH treatment of 
different concentrations (0, 0.1, 0.3 M) from the red marine algae, Kappaphycus alvarezii. The 
alkali played a vital role in the transformation of carrageenan to its Kappa (κ) form thus improving 
the gelling properties. The membranes were prepared by blending varying amounts of κ-
carrageenan (20-40 v/v % of the prepared solution) with the cross linked chitosan and genipin 
solutions. The model drug was loaded onto the films by “encapsulating” it between two layers of 
the pre-gel blend solution and vacuum dried. Drug release from the membranes was investigated 
in three different pH media (1.2, 4.5, and 6.8) and was measured by UV/Vis spectrophotometer. 
Carrageenan treated with different concentrations of KOH had an impact on the sulphate content 
and molecular weight. With increasing KOH concentration, the sulphate recovered was 17.13, 
15.72 & 8.71 % and the molecular weight was determined to be 64.2, 49.5, 8.2 ( x 105  g/mol ) 
respectively. This affected the gelling behaviour and as a result had an effect on the drug release 
profile. Membranes containing κ-carrageenan treated with 0.3 M KOH showed faster release of 
the drug than the carrageenan treated with 0.1 M KOH. However, there was little difference seen 
at a higher pH (6.8). This confirms that the release is responsive to pH changes. The release 
kinetics has been analyzed using the Zero order, First Order kinetic model, Higuchi plot and the 
Korsmeyer-Peppas model. 
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4. Fc receptor immunoreactivity at brain‐cerebrospinal fluid interfaces: 
implications for antibody delivery & distribution in the rat central nervous 
system (CNS) 
Geetika Nehra, Niyanta Kumar, Michelle Pizzo, Brynna Wilken‐Resman, Gretchen Greene, Sam 
Boroumand and Robert G. Thorne. Pharmaceutical Sciences Division, School of Pharmacy, 
University of Wisconsin – Madison, Madison WI 
Characterizing antibody distribution in the brain microenvironment is critical for successful 
translation of antibody therapies for treatment of central nervous system (CNS) disorders and is 
dependent on factors such as antibody binding to Fc receptors in the CNS. Surprisingly, the 
expression of these receptors in the CNS has not been well described. Here, we describe new 
studies using immunohistochemistry to investigate the distribution of two Fc receptors in the 
brain ‐ the inhibitory, low affinity‐binding (Kd ~ 10‐6 M) Fc gamma receptor (FcγRIIb) and the 
neonatal Fc receptor (FcRn) known to be involved in recycling/transport at peripheral interfaces. 
The expression of these receptors was studied at the nasal epithelia (olfactory and respiratory), 
trigeminal nerve, and lymph nodes in addition to the brain, dura and spinal cord. Our findings 
suggest that FcRn and FcγRIIb immunoreactivity is relatively high at the brain‐ cerebrospinal 
fluid (CSF) interfaces. We postulate that reversible binding of FcγRIIb with circulating IgG 
molecules at these interfaces may be limiting their distribution in the CNS. FcRn expression 
profiles were largely associated with immune cells, astrocytes, and cells at the brain‐CSF 
interfaces; some relatively low expression may also be present in the vascular endothelial cells. 
We hypothesize that such an expression pattern for FcRn may have an important influence on the 
uptake and transport of administered IgG within the CSF and brain. Overall, our findings may 
inform the engineering of antibody therapeutics for more efficient distribution within the CNS as 
well as provide a better perspective on physiological factors influencing endogenous IgG 
distribution. 
